


REMARKS

Claims 1-32 are active in the present application. Claims 3, 6, 10-14 and 19 have been amended to remove multiple dependencies. Claim 32 is a new claim. Support for the new claim is found in the original claims. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/kst

I:\atty\SUKOS\220513us-pr.wpd

Marked-Up Copy

Serial No:

Amendment Filed on:

3-14-2002

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows:

--3. (Amended) A formulation according to claim 1 [or 2] wherein estramustine phosphate is in the form of a pharmaceutically acceptable salt for parenteral use.

6. (Amended) A formulation according to [anyone of the preceding claims] claim 1 comprising estramustine phosphate and arginine in a molar ratio lower than 1:1.

10. (Amended) A formulation according to [any one of the preceding claims] claim 1 which is a single infusion dosage form comprising at least 1300 mg of the estramustine phosphate.

11. (Amended) A formulation according to [any one of the preceding claims] claim 1 which is in single infusion dosage form comprising at least 950 mg/m² of the estramustine phosphate.

12. (Amended) A formulation according to claim 10 [or 11] wherein the basic amino acid is arginine.

13. (Amended) A formulation according to [any one of the preceding claims] claim 1 for intravenous use.

14. (Amended) A formulation according to [any one of the preceding claims] claim 1 for use in the treatment of cancer.

19. (Amended) A product according to claim 17 [or 18] wherein the chemotherapeutic agent is selected from the group consisting of taxane derivatives such as paclitaxel and docetaxel; camptothecin and derivatives thereof such as CPT-11 and 9-amino-camptothecin; anthracycline derivatives such as doxorubicin, epirubicin, idarubicin, daunorubicin, alkycycline (4-demethoxy-3'-deamino-3'-aziridiny-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); etoposide; navelbine; vinblastine; platinum derivatives such as carboplatin and cisplatin; angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668; optionally within liposomal formulations thereof.

Claim 32 (New).--